ArticleDiabetes/metabolism research and reviews2020
DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19?
Article in Diabetes/metabolism research and reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Correlation between COVID-19 and hepatitis B: A systematic review.World journal of gastroenterology · 2022Pooled it
- A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19.Frontiers in endocrinology · 2021Trial
- Synthetic Approaches to Novel DPP-IV Inhibitors-A Literature Review.Molecules (Basel, Switzerland) · 2025Review
- "Hyperglycemic Memory": Observational Evidence to Experimental Inference.Current diabetes reviews · 2025Review
- Adenosine deaminase mediates endothelial inflammation via an ADA1-CD26 interaction in post-COVID.Frontiers in pharmacology · 2025Article
- Cognitive dysfunctions in the course of SARS‑CoV‑2 virus infection, including NeuroCOVID, frontal syndrome and cytokine storm (Review).Biomedical reports · 2024Review
- Stereochemical insights into β-amino-RSC advances · 2024Article
- Exploration of the link between COVID-19 and gastric cancer from the perspective of bioinformatics and systems biology.Frontiers in medicine · 2024Article
- Changes in Adenosine Deaminase Activity and Endothelial Dysfunction after Mild Coronavirus Disease-2019.International journal of molecular sciences · 2023Article
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19.Journal of pharmacy practice · 2023Review
- Hepatic Anti-Oxidative GenesAntioxidants (Basel, Switzerland) · 2023Article
- Glycemic control predicts SARS-CoV-2 prognosis in diabetic subjects.Acta diabetologica · 2023Observational
- Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.Clinical therapeutics · 2023Article
- Unique, Specific CART Receptor-Independent Regulatory Mechanism of CART(55-102) Peptide in Spinal Nociceptive Transmission and Its Relation to Dipeptidyl-Peptidase 4 (DDP4).International journal of molecular sciences · 2023Article
- The influence of COVID-19 on colorectal cancer was investigated using bioinformatics and systems biology techniques.Frontiers in medicine · 2023Article
- An improved Fuzzy based GWO algorithm for predicting the potential host receptor of COVID-19 infection.Computers in biology and medicine · 2022Article
- Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19.Diabetes/metabolism research and reviews · 2022Review
- Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology.Biomedicines · 2022Review
- Ovarian granulosa cells from women with PCOS express low levels of SARS-CoV-2 receptors and co-factors.Archives of gynecology and obstetrics · 2022Article
- Animal models for studying coronavirus infections and developing antiviral agents and vaccines.Antiviral research · 2022Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dipeptidyl peptidase 4 (DPP4), also known as cluster of differentiation 26 (CD26), is a serine exopeptidase expressed ubiquitously in several tissues, including but not limited to lung, kidney, liver, gut, and immune cells. The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19. A docked complex model of the SARS-CoV-2 spike glycoprotein and DPP4 has been proposed, showing a large interface between the proteins and proposing close similarity with other coronaviruses using DPP4 as functional receptor. In absence of experimental validation, these data should be interpreted with caution. Nevertheless, this observation may rise the question on whether DPP4 is directly involved in SARS-CoV-2 cell adhesion/virulence, and whether DPP4 inhibition might be a therapeutic strategy for preventing infection. Although a direct involvement of DPP4 in SARS-CoV-2 infection needs to be clarified, there is also evidence suggesting that DPP4 inhibitors modulate inflammation and exert anti-fibrotic activity. These properties may be of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19. Taken together these findings may suggest a potential role for DPP4 inhibition or modulation in one or more steps of COVID-19 immunopathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.